| [1] |
Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells[J]. Annu Rev Immunol, 2004, 22:891-928. doi:10.1146/annurev.immunol.22.012703.104543URL |
| [2] |
Cacalano G, Lee J, Kikly K, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog[J]. Science, 1994, 265(5172):682-684. pmid:8036519 |
| [3] |
Heidemann J, Ogawa H, Dwinell MB, et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2[J]. J Biol Chem, 2003, 278(10):8508-8515. doi:10.1074/jbc.M208231200pmid:12496258 |
| [4] |
Robinson S, Cohen M, Prayson R, et al. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas[J]. Neurosurgery, 2001, 48(4):864-873; pmid:11322447 |
|
discussion 873-864. pmid:11322447 |
| [5] |
Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner[J]. Mol Cancer Res, 2012, 10(10):1294-1305. doi:10.1158/1541-7786.MCR-12-0275pmid:22893608 |
| [6] |
Hiroaki K, Masakazu Y, Hirohisa N, et al. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma[J]. PLoS One, 2017, 12(6):e0178635. doi:10.1371/journal.pone.0178635URL |
| [7] |
刘立, 盖金娜, 尹作文, 等. 趋化因子CXCL5调控NF-κB与Wnt/β-catenin信号通路抑制肿瘤免疫促进胃癌的机制研究[J]. 肿瘤防治研究, 2020, 47(5):340-345. |
| [8] |
Wang Z, Liu H, Shen Z, et al. The prognostic value of CXC-chemokine receptor 2(CXCR2) in gastric cancer patients[J]. BMC Cancer, 2015, 15:766. doi:10.1186/s12885-015-1793-9URL |
| [9] |
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203):436-444. doi:10.1038/nature07205URL |
| [10] |
Mantovani A. The chemokine system: redundancy for robust outputs[J]. Immunol Today, 1999, 20(6):254-257. pmid:10354549 |
| [11] |
Allavena P, Germano G, Marchesi F, et al. Chemokines in cancer related inflammation[J]. Exp Cell Res, 2011, 317(5):664-673. doi:10.1016/j.yexcr.2010.11.013pmid:21134366 |
| [12] |
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation[J]. Trends Mol Med, 2010, 16(3):133-144. doi:10.1016/j.molmed.2010.01.003pmid:20163989 |
| [13] |
Waugh DJ, Wilson C. The interleukin-8 pathway in cancer[J]. Clin Can Res, 2008, 14(21):6735-6741. doi:10.1158/1078-0432.CCR-07-4843URL |
| [14] |
Wang RX, Ji P, Gong Y, et al. Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study[J]. Breast Cancer Res Treat, 2020, 181(3):561-570. doi:10.1007/s10549-020-05660-zURL |
| [15] |
Awaji M, Saxena S, Wu L, et al. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancrea-tic ductal adenocarcinoma[J]. FASEB J, 2020, 34(7):9405-9418. doi:10.1096/fj.201902990RURL |
| [16] |
Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor[J]. Science, 1991, 253(5025):1280-1283. pmid:1891716 |
| [17] |
Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor[J]. Science, 1991, 253(5025):1278-1280. pmid:1840701 |
| [18] |
Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology.ⅩⅫ. Nomenclature for chemokine receptors[J]. Pharmacol Rev, 2000, 52(1):145-176. pmid:10699158 |
| [19] |
Murdoch C, Monk PN, Finn A. CXC chemokine receptor expression on human endothelial cells[J]. Cytokine, 1999, 11(9):704-712. pmid:10479407 |
| [20] |
Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity[J]. J Immunol, 2000, 165(9):5269-5277. doi:10.4049/jimmunol.165.9.5269pmid:11046061 |
| [21] |
徐佶, 张一楚. Bcl基因与Ki-67抗原在胃癌组织中表达的研究[J]. 外科理论与实践, 1998, 3(1):18-20. |
| [22] |
Yang G, Rosen DG, Liu G, et al. CXCR2 promotes ova-rian cancer growth through dysregulated cell cycle, dimi-nished apoptosis, and enhanced angiogenesis[J]. Clin Can-cer Res, 2010, 16(15):3875-3886. |